Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Increased expression of fatty acid synthase in human aberrant crypt foci: possible target for colorectal cancer prevention.

Kearney KE, Pretlow TG, Pretlow TP.

Int J Cancer. 2009 Jul 1;125(1):249-52. doi: 10.1002/ijc.24356.

2.

Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".

Stevens RG, Pretlow TP, Hurlstone DP, Giardina C, Rosenberg DW.

Cancer Prev Res (Phila). 2008 Aug;1(3):215-6; author reply 216. doi: 10.1158/1940-6207.CAPR-08-0094. No abstract available.

3.

Aberrant crypt foci: what we know and what we need to know.

Gupta AK, Pretlow TP, Schoen RE.

Clin Gastroenterol Hepatol. 2007 May;5(5):526-33. Epub 2007 Apr 12. Review.

PMID:
17433788
4.

15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.

Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD.

Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12098-102. Epub 2006 Jul 31.

5.

Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer.

Luo L, Shen GQ, Stiffler KA, Wang QK, Pretlow TG, Pretlow TP.

Carcinogenesis. 2006 Jun;27(6):1153-9. Epub 2006 Feb 12.

PMID:
16474178
6.

Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer?

Pretlow TP, Pretlow TG.

Biochim Biophys Acta. 2005 Nov 25;1756(2):83-96. Epub 2005 Jul 18. Review.

PMID:
16219426
7.

Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD.

J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32.

PMID:
16077070
8.

CpG island methylation in aberrant crypt foci and cancers from the same patients.

Luo L, Chen WD, Pretlow TP.

Int J Cancer. 2005 Jul 10;115(5):747-51.

9.

Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer.

Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB.

Nat Genet. 2004 Apr;36(4):417-22. Epub 2004 Mar 14.

PMID:
15034581
10.

Spontaneous aberrant crypt foci in Apc1638N mice with a mutant Apc allele.

Pretlow TP, Edelmann W, Kucherlapati R, Pretlow TG, Augenlicht LH.

Am J Pathol. 2003 Nov;163(5):1757-63.

11.
12.

SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.

Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7. Epub 2003 Jun 26.

13.

Pathology of mouse models of intestinal cancer: consensus report and recommendations.

Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey RJ.

Gastroenterology. 2003 Mar;124(3):762-77. Review. No abstract available.

PMID:
12612914
14.

Beta-catenin expression and allelic loss at APC in sporadic colorectal carcinogenesis.

Hao X, Frayling IM, Willcocks TC, Han W, Tomlinson IP, Pignatelli MN, Pretlow TP, Talbot IC.

Virchows Arch. 2002 Apr;440(4):362-6. Epub 2002 Jan 25.

PMID:
11956815
15.

Differential experimental micrometastasis to lung, liver, and bone with lacZ-tagged CWR22R prostate carcinoma cells.

Holleran JL, Miller CJ, Edgehouse NL, Pretlow TP, Culp LA.

Clin Exp Metastasis. 2002;19(1):17-24.

PMID:
11918079
16.

Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon.

Hardy RG, Tselepis C, Hoyland J, Wallis Y, Pretlow TP, Talbot I, Sanders DS, Matthews G, Morton D, Jankowski JA.

Gut. 2002 Apr;50(4):513-9.

17.

Beta-catenin expression is altered in human colonic aberrant crypt foci.

Hao XP, Pretlow TG, Rao JS, Pretlow TP.

Cancer Res. 2001 Nov 15;61(22):8085-8.

19.
20.

Prostate cancer and other xenografts from cells in peripheral blood of patients.

Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLennan GT, Resnick MI, Pretlow TP, Connell CF.

Cancer Res. 2000 Aug 1;60(15):4033-6.

21.

Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.

Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP.

Cancer Res. 2000 Jan 1;60(1):18-21.

22.

A new human prostate carcinoma cell line, 22Rv1.

Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW.

In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9.

PMID:
10462204
23.

Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors.

Kochera M, Depinet TW, Pretlow TP, Giaconia JM, Edgehouse NL, Pretlow TG, Schwartz S.

Prostate. 1999 Sep 15;41(1):7-11.

PMID:
10440870
24.

The identification of monoclonality in human aberrant crypt foci.

Siu IM, Robinson DR, Schwartz S, Kung HJ, Pretlow TG, Petersen RB, Pretlow TP.

Cancer Res. 1999 Jan 1;59(1):63-6.

25.

Putative preneoplastic changes identified by enzyme histochemical and immunohistochemical techniques.

Pretlow TP, Pretlow TG.

J Histochem Cytochem. 1998 May;46(5):577-83. Review.

PMID:
9606105
26.

Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer.

Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG.

J Natl Cancer Inst. 1998 Apr 1;90(7):519-23.

PMID:
9539247
27.

Identification of dysplasia in human colonic aberrant crypt foci.

Siu IM, Pretlow TG, Amini SB, Pretlow TP.

Am J Pathol. 1997 May;150(5):1805-13.

28.

Aberrant crypt foci in the colonic mucosa of rats treated with a genotoxic and nongenotoxic colon carcinogen.

Whiteley LO, Hudson L Jr, Pretlow TP.

Toxicol Pathol. 1996 Nov-Dec;24(6):681-9.

PMID:
8994294
29.

Altered expression of CD44 in human prostate cancer during progression.

Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS.

Am J Clin Pathol. 1996 Nov;106(5):647-51.

PMID:
8929476
30.

Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer.

Konstantakos AK, Siu IM, Pretlow TG, Stellato TA, Pretlow TP.

Gastroenterology. 1996 Sep;111(3):772-7.

PMID:
8780584
31.

CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG.

Cancer Res. 1996 Jul 1;56(13):3042-6.

32.

Expression of E-cadherin in primary and metastatic prostate cancer.

Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG.

Am J Pathol. 1996 May;148(5):1375-80.

33.

Evidence for genomic instability in human colonic aberrant crypt foci.

Augenlicht LH, Richards C, Corner G, Pretlow TP.

Oncogene. 1996 Apr 18;12(8):1767-72.

PMID:
8622897
34.

Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2'-dimethyl-4-aminobiphenyl.

Feng Y, Wagner RJ, Fretland AJ, Becker WK, Cooley AM, Pretlow TP, Lee KJ, Hein DW.

Cancer Res. 1996 Feb 1;56(3):527-31.

35.

Prostatic intraepithelial neoplasia and other changes during promotion and progression.

Pretlow TG, Nagabhushan M, Pretlow TP.

Pathol Res Pract. 1995 Sep;191(9):842-9. Review.

PMID:
8606863
36.

Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon.

Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E, Gerson SL.

Carcinogenesis. 1995 Mar;16(3):451-6.

PMID:
7697797
37.

Organ culture of benign, aging, and hyperplastic human prostate.

Pretlow TG, Yang B, Pretlow TP.

Microsc Res Tech. 1995 Mar 1;30(4):271-81. Review.

PMID:
7541675
38.

Aberrant crypt foci and K-ras mutations: earliest recognized players or innocent bystanders in colon carcinogenesis?

Pretlow TP.

Gastroenterology. 1995 Feb;108(2):600-3. No abstract available.

PMID:
7835604
39.

Carcinoembryonic antigen in human colonic aberrant crypt foci.

Pretlow TP, Roukhadze EV, O'Riordan MA, Chan JC, Amini SB, Stellato TA.

Gastroenterology. 1994 Dec;107(6):1719-25.

PMID:
7958683
40.

CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, et al.

Cancer Res. 1994 Dec 1;54(23):6049-52.

41.

A novel approach to the characterization of whole prostate pathology in glycol methacrylate.

Monger LE Jr, Nagabhushan M, Pretlow TG, Pretlow TP.

Am J Pathol. 1994 Jul;145(1):54-60.

42.

Aberrant crypt foci and colon tumors in F344 rats have similar increases in proliferative activity.

Pretlow TP, Cheyer C, O'Riordan MA.

Int J Cancer. 1994 Feb 15;56(4):599-602.

PMID:
8112897
43.

Putative preneoplastic foci in the human prostate.

Pretlow TG, Nagabhushan M, Sy M, Guo Y, Pretlow TP.

J Cell Biochem Suppl. 1994;19:224-31. Review.

PMID:
7529854
44.

K-ras mutations in putative preneoplastic lesions in human colon.

Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL.

J Natl Cancer Inst. 1993 Dec 15;85(24):2004-7.

PMID:
8246286
45.

A better defined medium for human prostate cancer cells.

Pretlow TG, Ogrinc GS, Amini SB, Delmoro CM, Molkentin KF, Willson JK, Pretlow TP.

In Vitro Cell Dev Biol Anim. 1993 Jul;29A(7):528-30. No abstract available.

PMID:
8354663
46.
47.
48.

Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate.

Pretlow TP, O'Riordan MA, Somich GA, Amini SB, Pretlow TG.

Carcinogenesis. 1992 Sep;13(9):1509-12.

PMID:
1394832
50.

Aberrant crypts in human colonic mucosa: putative preneoplastic lesions.

Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA.

J Cell Biochem Suppl. 1992;16G:55-62. Review.

PMID:
1361589

Supplemental Content

Loading ...
Support Center